Cue Biopharma, Inc.
CUEOther · Non-accelerated filer<br>Smaller reporting company · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M | $3.2M |
| Operating income | −$26.6M | −$41.5M | −$52.1M | −$53.2M | −$43.7M | −$45.0M |
| Net income | −$26.6M | −$40.7M | −$50.7M | −$53.0M | −$44.2M | −$44.8M |
| Total assets | $42.2M | $32.2M | $61.5M | $91.3M | $83.4M | $99.5M |
| Total liabilities | $15.8M | $14.7M | $24.4M | $25.6M | $17.9M | $20.6M |
| Equity | $26.4M | $17.5M | $37.1M | $65.7M | $65.5M | $78.9M |
| EPS (diluted) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 | — |
| Shares out. | 61.8M | 48.6M | 43.2M | 33.0M | 30.5M | 26.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −96.7%
- Net margin
- −96.9%
- Return on equity
- −100.6%
- Return on assets
- −63.0%
- Return on capital (ROCE)
- −92.5%
- Liabilities / assets
- 37.4%
- Debt / equity
- 0.60×
- Book value / share
- $0.43
- Revenue growth (YoY)
- 195.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -27.27distress
- Accruals / assets
- −11.6%clean
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Lin Shao-LeeOfficer — CHIEF EXECUTIVE OFFICER | May 3, 2026 | Grant | 327,537 | $0.00 |
| Sarraf PashaDirector | Dec 30, 2025 | Buy | 4,229 | $0.31 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 255,157 | 1.0 | -11.7% |
| Apr 30, 2026 | 288,887 | 1.0 | -96.2% |
| Apr 15, 2026 | 7.5M | 1.0 | +183.1% |
| Mar 31, 2026 | 2.7M | 1.0 | +17.2% |
| Mar 13, 2026 | 2.3M | 2.1 | +27.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Unregistered equity sale · Director / officer change · Other material eventMay 1, 2026
- Modified shareholder rights · Amended charter or bylawsApr 22, 2026
- Shareholder voteApr 13, 2026
- Other material eventApr 7, 2026
- Director / officer changeMar 27, 2026
- Results of operationsMar 16, 2026
- Other material eventFeb 18, 2026
- Director / officer changeFeb 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.